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Background: Human papilloma virus (HPV) is the causative agent of cervical neoplasia and genital warts. A
vaccine has recently been developed that may prevent infection with HPV. Vaccination for HPV may become a
routine part of ofﬁce gynecology. We surveyed members of the American College of Obstetricians and
Gynecologists (ACOG) to determine their attitudes to HPV vaccination.
Methods: A survey was sent to Fellows of ACOG to evaluate gynecologists’ attitudes. Vaccine acceptability was
analyzed using 13 scenarios with the following dimensions and respective attributes: age of patient (3, 17 and 22
years); efﬁcacy of vaccine (50% or 80%); ACOG recommendation (yes or no); and disease targeted (cervical
cancer, warts or both). Each scenario was rated by means of an 11-point response format (0 to 100). Responses
were evaluated using conjoint analysis.
Results: Of 1200surveys that were sent out, 181 were returned and included in our analysis. ACOG
recommendation was considered the most important variable in vaccine distribution (importance score=32.2),
followed by efﬁcacy (24.5), age (22.4) and, lastly, disease targeted (20.9). Of these variables, higher efﬁcacy was
favored; preference was given to age 17 years, with a strong disinclination to vaccinate at age 13 years; and
protection against cervical cancer, or genital warts, or both, was signiﬁcantly favored over a vaccine against
genital warts alone. Demographic characteristics of the gynecologists (i.e., age of physician, gender, practice
setting and community size) did not play an important role in the decision to recommend vaccination.
Conclusion: Professional society recommendation is important for acceptability of a potential HPV vaccine.
Gynecologists are willing to include this vaccine in their ofﬁce practice.
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INTRODUCTION
Human papilloma virus (HPV) infections are
common, with a prevalence of 10 to 20% in the
general population(1) and up to 46% in university
students(2,3). It has been found that virtually all
cervical cancers are associated with HPV infec-
tion(4,5), 50% being caused by HPV-16(5). The
prevalence of HPV varies with age, with the
highest prevalence in the age range 20 to 30
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developed and studied in human subjects.
One of the vaccines developed uses virus-like
particles (VLPs) that are synthetically produced L1
gene proteins which form an empty capsid. The
L1 gene is part of the HPV genome which
encodes for a protein that self-assembles into a
viral capsid which is immunogenic when available
to the immune system(7). The vaccine has VLPs,
or empty capsids, which are presented as
conformational epitopes which induce an im-
mune response greater than do live virons(7,8). In
2002, it was reported that a vaccine composed of
HPV 16 L1 VLPs reduced the prevalence of both
HPV 16 infection and related cervical intrae-
pithelial neoplasia. The estimated efﬁcacy of this
vaccine was 90 to 100%(9).
As vaccines are developed for clinical practice,
the willingness of physicians to recommend HPV
vaccination will be one essential element for the
successful implementation of HPV immunization
programs. This study examines the acceptability
to gynecologists of HPV vaccination for their
patients as a function of physician preferences for
key vaccine-related characteristics.
METHODS
A survey was distributed to a random subset of
1200 Fellows of the American College of
Obstetricians and Gynecologists (ACOG)
throughout the USA. This subset was graciously
provided by the research ofﬁce of ACOG. The
survey included 13 scenarios to evaluate vaccine
acceptability with regard to the following four
dimensions and respective attributes: ACOG
approval (yes or no); vaccine efﬁcacy (50% or
80%); age of patient (13, 17 or 22 years); and
targeted disease (cervical cancer, genital warts or
both).
For example, the ﬁrst item read as follows:
‘‘Scenario 1: The patient is a 13-year-old girl and
is not sexually active. The vaccine is effective
against HPV types that cause both cervical cancer
and genital warts. Efﬁcacy of the vaccine is 80%.
The American College of Obstetricians and
Gynecologists (ACOG) has recommended this
vaccine be given.’’
All 13 scenarios are shown in the Appendix. An
11-point scale was used to access physician
willingness to recommend vaccination to the
patient in each scenario. The scale ranged from 0
(never recommend), through 50 (unsure), to 100
(deﬁnitely recommend) in increments of 10. The
physician was asked to evaluate each scenario and
circle the number that indicated the likelihood of
recommending the vaccine described to the
patient. Demographic data were collected, in-
cluding physician age, gender, community setting,
practice setting, year of residency and clinic visits
used to treat genital warts and cervical dysplasia.
This study involved four dimensions with two
to three attributes for each dimension. To list
every possible scenario in the survey, 36 vaccine
scenarios would have been required. A subset of
nine scenarios was developed using a fractional
factorial design through the SPSS Conjoint
procedure(10). This method allowed the devel-
opment of a conjoint model which predicted
responses to every vaccine scenario based on the
smaller subset. This statistical method was used to
quantify the importance of each dimension to the
vaccine acceptability as a whole. The limitation of
this model is that the interactions of dimensions
with one another cannot be evaluated. Conjoint
analytic methods increasingly have been applied
to research on medical decision-making issues,
including acceptability of vaccination(11,12).
Four hold-out scenarios were also developed
by the conjoint procedure in order to assess the ﬁt
of the conjoint model. Thus, these four items
were not used in the development of the conjoint
model, but were used to evaluate how closely the
model predicted the actual scores associated with
those items. The association between the actual
scores and the model-predicted scores could be
assessed using a Pearson correlation.
The mean rating of all 13 scenarios assessed
overall vaccine acceptability. Full-proﬁle, ratings-
based conjoint analysis was used for the statistical
analysis. Part-worth utilities were calculated
reﬂecting the physicians’ relative preferences for
the attributes within a given dimension, e.g. a
recommendation from ACOG versus no recom-
mendation from ACOG. A more positive part-
worth utility score would indicate that the given
answer was more highly valued. The relative
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converted into importance scores indicating
which of the four dimensions were viewed as
more signiﬁcant in vaccine recommendation. In
this statistical method, the sum of all importance
scores always equals 100. The highest importance
score in the series of four dimensions indicates
that this is overall the most valued dimension.
The institutional review board of the Uni-
versity of Iowa approved this survey and research
protocol.
RESULTS
In all 207 gynecologists returned the survey; 26
respondents assigned the same rating to all of the
nine scenarios, including 21 who gave a rating of
100 to all nine scenarios. Because these ratings did
not vary across scenarios, preferences based on
scenario dimensions could not be evaluated. As a
result, their surveys could not be used in the
conjoint analysis. Therefore, 181 respondent
surveys were used to develop our conjoint model.
A conjoint model ﬁt was calculated by Pearson
correlations between the actual respondent’s
ratings of 4 hold-out conjoint scenarios and the
predicted value of those scenarios based on the
conjoint model. The median Pearson correlation
was 0.85, indicating a very good ﬁt for the
conjoint model. The demographics for the
responders are included in Table I. The overall
scenario ratings were not signiﬁcantly associated
with any of the demographic information about
the respondents. Across all scenarios used in the
model, the mean acceptance of vaccination was
79.0, standard deviation 16.6 (scale of 0 to 100).
The part-worth utilities showing physician
preference for each attribute were calculated and
are displayed in Figure 1A and B. In Figure 1A,
gynecologists answering our survey strongly
preferred an ACOG recommendation and a more
efﬁcacious vaccine. As shown in 1B, the survey
respondents were disinclined to vaccinate 13-
year-olds. As also shown in this ﬁgure, the
respondents preferred a vaccine that was directed
against HPV types associated with cervical
neoplasia and genital warts or a vaccine against
oncogenic HPV types only. There was less
acceptance of a vaccine targeting only HPV types
causing genital warts.
The relative ranges for the part-worth utilities
were converted into importance scores and are
displayed in Figure 2. ACOG approval contrib-
uted most strongly to ratings inﬂuencing
physician recommendation, with an importance
score of 32.2, followed by vaccine efﬁcacy,
patient age and vaccine type.
DISCUSSION
The purpose of our study was to examine how
vaccine-related characteristics inﬂuenced gyne-
cologists’ acceptance of HPV vaccination for
patients. The characteristics in which we were
interested included ACOG approval, vaccine
efﬁcacy, age of patient and disease targeted in
the vaccine.
Our study found that the professional organi-
zation’s recommendation was the variable that
most inﬂuenced the gynecologists’ choice
whether to recommend the vaccine to the
patient. This ﬁnding echoes the results of a recent
Table 1 Demographic characteristics for the survey respondents
Characteristic ? Values ?
Age in years Mean 47.1 Range 30–72 SD 10.7
Years in practice Mean 16.2 Range 1–42 SD 28.1
Gender 55 % male 45% female ?
Work setting 28% urban 56% suburban 15% rural
Practice type 62% solo 19.5%, teaching 18.5%, multispecialty
Community size 34% large* 30% mod{,
22% city{
14% small,**
1% rural{{
*Large city, population more than 500000; {moderate city, population 100000 to 499999; {city, population 25000 to 100000; **small
town, population 5000 to 24999; {{rural, population less than 4999.
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vaccination, in which endorsement by the
American Academy of Pediatrics was a very
important determinant of nurses’ willingness to
recommend immunization(11,12). This trend was
also documented when universal hepatitis B
immunization was recommended. Freed et al.
recorded that although 82% of pediatricians knew
of the recommendation by the Committee on
Immunization Practice for Hepatitis B Vaccina-
tion, only 37% agreed that this was warranted.
After the American Academy of Pediatrics and
the American Academy of Family Physicians gave
their recommendations for vaccination, 66% of
pediatricians agreed universal immunization was
warranted(13). The recommendation of HPV
vaccination by ACOG as well as other profes-
sional peer groups will be very important to a
successful vaccination program.
We found it most interesting that the
gynecologists were disinclined to vaccinate 13-
year-olds, a ﬁnding also reported in the nurse
Figure 1A and B Part-worth utilities. Higher positive scores indicate more acceptance of that attribute or answer.
More negative scores indicate less acceptance
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common that the chances of getting the
infection after one sexual contact are high.
Silins et al. reported a correlation between
lifetime sexual partners and the prevalence of
seropositivity for HPV in Swedish females who
had a mean age of 26 years(14). They found that
the prevalence of seropositivity rose with the
number of sexual partners, from 10% with one
partner, and 25% with two or three partners and
to 53% with more than 6 partners. Another
study reported that each additional sexual
partner added about 10% to the risk of HPV
infection(15). Thus the prevalence of infection
rapidly increases with the number of partners.
Because of the early onset of sexual activity,
acceptance of multiple sexual partners and
cervical immaturity, 13-year-olds might be the
best candidates for a prophylactic HPV vaccine.
However, this was the age group for which the
vaccine was least likely to be recommended by
the gynecologists surveyed. It will be important
to include physician education as an essential
part of a vaccine implementation program in the
ofﬁces of gynecologists and other practitioners
who care for adolescent women.
The major limitation of this study was the low
response rate of 17.3%. In an attempt to maximize
our response rate, we devized a short survey;
preliminary survey respondents reported that this
took 5 to 10 minutes to complete. We also sent a
second reminder letter. Our survey respondents
were anonymous and were all physicians. In other
studies these characteristics decreased the respon-
dence rate by 14 and 9%, respectively(16). A
meta-analysis of physician surveys found little
difference in demographic variables among early
responders, respondents to subsequent mailings,
and late responders. This was thought to be
because physicians are a more homogeneous
group with regard to knowledge, attitudes and
behavior. The analysis concluded that a non-
response bias might not be as critical to
interpretation of data gathered from physician
surveys with low response rates compared with
the general population(17).
Our ﬁndings show that an HPV vaccine will
be widely accepted (79.0%) for use by gynecol-
ogists. The results also point to the importance of
ACOG approval in future HPV immunization
practices as well as high vaccine efﬁcacy.
Physicians seem to approve more of a vaccine
that can combat both types of targeted disease
rather than warts alone. Physicians appeared to be
uncomfortable about immunizing 13-year-olds,
although this may be an excellent age group to
target in the prevention of HPV infections. We
feel conﬁdent that gynecologists will accept an
HPV vaccine as part of their routine gynecolo-
gical practice.
Figure 2 Importance scores. The highest score indicates that this characteristic was most inﬂuential in respondents’
ratings of the vaccine scenarios
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Scenario 1: The patient is a 13-year-old girl and is
not sexually active. The vaccine is effective
against HPV types that cause both cervical cancer
and genital warts. Efﬁcacy of the vaccine is 80%.
The American College of Obstetricians and
Gynecologists (ACOG) has recommended that
this vaccine be given.
Scenario 2: The patient is a 13-year-old girl
and is not sexually active. The vaccine is effective
against HPV types that cause both cervical cancer
and genital warts. Efﬁcacy of the vaccine is 80%.
ACOG has not recommended for or against
administration of this vaccine.
Scenario 3: The patient is a 22-year-old
woman with three lifetime sexual partners. The
vaccine is effective against HPV types that cause
cervical cancer. Efﬁcacy of the vaccine is 80%.
ACOG has not recommended for or against
administration of this vaccine.
Scenario 4: The patient is a 22-year-old
woman with three lifetime sexual partners. The
vaccine is effective against HPV types that cause
both cervical cancer and genital warts. Efﬁcacy of
the vaccine is 50%. ACOG has not recommended
for or against administration of this vaccine.
Scenario 5: The patient is a 13-year-old girl
and is not sexually active. The vaccine is effective
against HPV types that cause cervical cancer.
Efﬁcacy of the vaccine is 80%. ACOG has not
recommended for or against administration of this
vaccine.
Scenario 6: The patient is a 17-year-old girl
and is not sexually active but is seeking contra-
ception. The vaccine is effective against HPV
types that cause cervical cancer. Efﬁcacy of the
vaccine is 50%. ACOG has recommended that
this vaccine be given.
Scenario 7: The patient is a 22-year-old
woman with three lifetime sexual partners. The
vaccine is effective against HPV types that cause
genital warts. Efﬁcacy of the vaccine is 50%.
ACOG has recommended that this vaccine be
given.
Scenario 8: The patient is a 17-year-old girl
and is not sexually active but is seeking contra-
ception. The vaccine is effective against HPV
types that cause both cervical cancer and genital
warts. Efﬁcacy of the vaccine is 80%. ACOG has
recommended that this vaccine be given.
Scenario 9: The patient is a 17-year-old girl
and is not sexually active but is seeking contra-
ception. The vaccine is effective against HPV
types that cause genital warts. Efﬁcacy of the
vaccine is 80%. ACOG has not recommended for
or against administration of this vaccine.
Scenario 10: The patient is a 13-year-old girl
and is not sexually active. The vaccine is effective
against HPV types that cause genital warts.
Efﬁcacy of the vaccine is 80%. ACOG has
recommended that this vaccine be given.
Scenario 11: The patient is a 22-year-old
woman with three lifetime sexual partners. The
vaccine is effective against HPV types that cause
both cervical cancer and genital warts. Efﬁcacy of
the vaccine is 50%. ACOG has recommended
that this vaccine be given.
Scenario 12: The patient is a 13-year-old girl
and is not sexually active. The vaccine is effective
against HPV types that cause cervical cancer.
Efﬁcacy of the vaccine is 80%. ACOG has
recommended that this vaccine be given.
Scenario 13: The patient is a 22-year-old
woman with three lifetime sexual partners. The
vaccine is effective against HPV types that cause
both cervical cancer and genital warts. Efﬁcacy of
the vaccine is 80%. ACOG has recommended
that this vaccine be given.
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